Daniel Catenacci,MD, associate professor of medicine ( Hematology/Oncology) has been named as the recipient of the National Cancer Institute (NCI) 2021 Cancer Clinical Investigator Team Leadership Award. Established in 2009, the award recognizes outstanding clinical investigators at NCI-designated cancer centers who participate extensively in NCI-funded clinical trials and whose leadership and activities promote a successful culture of collaborative clinical research.
Dr. Catenacci is an adult gastrointestinal medical oncologist and director of the Gastrointestinal Oncology Program at the University of Chicago. He also serves as the assistant director of translational research in the Comprehensive Cancer Center. In addition to his clinical practice, Dr. Catenacci is an active basic and clinical researcher, focusing on the treatment of gastroesophageal (esophagus, gastroesophageal junction, and stomach) cancers. His bench-to-bedside translational research has an overarching goal to validate and improve personalized treatment, immunotherapy, and precision medicine for gastroesophageal cancer and other GI cancers. A major focus of his research is on the quantification of tumor genetic molecular heterogeneity both between individuals with gastroesophageal cancer, but importantly also within a given individual within one tumor site, and from one tumor site to another, and how this impacts personalized targeted therapeutic approaches. Additionally, Dr. Catenacci designs and executes novel clinical trials to implement treatment strategies based on these laboratory and clinical discoveries.
More information about Dr. Catenacci’s award may be found here